By Saher Valiani, Matt Holian and Jill Marinoff

Developments in technology are driving major change across all sectors and, in many cases, these changes are significantly impacting legal developments in a particular industry. In the past, pharmaceutical and medical device product liability litigations typically commenced following major regulatory action
Continue Reading An intersection of technology and life sciences: The impact of big data and social media

As banks and other financial services companies adopt cloud computing for a variety of purposes, questions about the operational risks involved have emerged. In order to use the cloud, many banks are depending on cloud service providers to protect sensitive information rather than managing their own systems, with the potential
Continue Reading Cloud computing in the financial services sector

By  Victoria Lee and Andrew W. Grant

On September 12, 2019, the Task Force on Artificial Intelligence, which is a task force within the House Financial Services Committee (FSC), held a hearing titled “The Future of Identity in Financial Services: Threats, Challenges, and Opportunities.” As the FSC wrote before the
Continue Reading Task Force on Artificial Intelligence hearing: the future of identity in financial services – key testimony on threats, challenges, opportunities

By Gregory Grossman and Heidi Azulay

The market for companies working at the intersection of real estate and technology is seeing explosive growth, as innovative new forms of technology impact how properties are constructed, occupied, managed, bought and sold.

Proptech is designed to streamline and connect processes for participants in
Continue Reading Disrupting the real estate industry: emerging trends in proptech

Trial and error – with the vast majority of trials ending in error – has long been the default method of drug discovery. Of the USD2.6 billion spent each year on drug discovery by the world’s largest pharmaceutical companies, at least nine-tenths will go toward funding drug research that will
Continue Reading The error of trials: Legal considerations when deploying AI in drug development